Aloin-A (Standard)

Aloin (Standard) is the analytical standard of Aloin. This product is intended for research and analytical applications. Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) [1][2][3][4].

Product Specifications

CAS Number

[1415-73-2]

Product Name Alternative

Barbaloin-A (Standard)

UNSPSC

12352005

Target

Reference Standards; Wnt

Type

Reference Standards

Related Pathways

Others; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aloin-standard.html

Smiles

O=C1C2=C(C=CC=C2O)[C@H]([C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C4=CC(CO)=CC(O)=C14

Molecular Formula

C21H22O9

Molecular Weight

418.39

References & Citations

[1]Pan Q, et al. Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo. Cancer Cell Int. 2013 Jul 12;13 (1) :69.|[2]Tabolacci C, et al. Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. Amino Acids. 2013 Jan;44 (1) :293-300.|[3]Cui Y, et al. Aloin protects against chronic alcoholic liver injury via attenuating lipid accumulation, oxidative stress and inflammation in mice. Arch Pharm Res. 2014 Dec;37 (12) :1624-33.|[4]Pengjam Y, et al. Anthraquinone Glycoside Aloin Induces Osteogenic Initiation of MC3T3-E1 Cells: Involvement of MAPK Mediated Wnt and Bmp Signaling. Biomol Ther (Seoul) . 2016 Mar 1;24 (2) :123-3|[5]Jing Y, et al. Aloin Protects Against Blood-Brain Barrier Damage After Traumatic Brain Injury in Mice. Neurosci Bull. 2020 Jun;36 (6) :625-638.